Abstract Clinical pre-test probability scores are used to guide the subsequent steps in the diagnosis and therapy of venous thromboembolism. However, often there is resistance in accepting formal and standardized procedures as a substitute of expert judgements. A review of the available tools as well as of the laboratory and imaging techniques is presented, together with the detailed report of a comprehensive debate held on the Vasculab Mailing List. Several unusual topics came to attention during the discussion: as the validation of scores, limited to a few contexts and populations; the over-utilization of venous duplex ultrasound and the rational use of resources; how to choose the steps, managing the amount of time waiting for the results of a test; the scarce attention given today to the long term complications, like the chronic pulmonary embolism, the pulmonary hypertension and the postthrombotic syndrome. A lot of open problems of course remains, the report being witness of the value of a free style atypical discussion, as generally occurs on Vasculab.
Introduction
Venous thromboembolism (VTE) has gained an increased attention in the last years, owing to our better diagnostic capability and to the availability of new therapeutic choices. Most used acronyms are listed to insure a better comprehension (Table I ).
The most common symptom of calf pain has been reported to have sensitivity between 75% and 91%, and specificity between 3% and 87%. The reported sensitivity of calf swelling for Deep Veins Thrombosis (DVT) diagnosis ranges from 35% to 97%, and its reported specificity ranges from 8% to 88%. In part, such variability is due to the high prevalence of the same signs and symptoms in patients without DVT 1, 2 .
Swelling and generally signs of lower limb thrombosis are not the main clinical presentation of VTE, which instead can present itself as a chest pain or a primary respiratory failure with hypoxia, which can or cannot be associated to a lower limb thrombosis.
Interestingly, the idea of using risk assessment as the first step in the diagnosis of VTE was developed and promulgated when general consensus was that clinical presentation is unreliable.
The approach was initially developed for symptomatic outpatients, and most frequently used pretest probability (PTP) instruments are validated only in restricted environments and their application remains uncertain for other patient populations, such as pregnant and post-partum women. Instruments that are designed for in-patients are designed for prevention, not for diagnosis of VTE. In addition, between inpatients the greater frequency of DVT is given by adverse effects in medical patients (like for instance post ictus and myocardial infarction), greater than the rate of the well-known VTE in post-operative period (especially in orthopaedic and gynaecologic surgery).
The incidence of VTE changes according to the clinical environment where the patient comes to our observation. Outpatients have a different prevalence of DVT and pulmonary embolism (PE), compared to inpatients and to emergency patients.
Occurrence of provoked VTE now encompasses clinical scenarios that we did not have 20 years ago. For example, the shift is towards seeing more VTE in intensive care units, where the average stay has increased and patients are maintained on life support longer. Unprovoked VTE on the other hand surely is seen more than before probably due to better access to ultrasound. We are probably at a point where studies on current VTE incidences may have to be repeated.
These facts, some of them reported only in a qualitative way, constitute a stimulus to look at VTE as an interdisciplinary pathology, which changes its presentation as soon as you change your point of view, i.e. your working environment.
Applicability of the entire approach as well as of the adopted instruments to other patient populations remains questionable.
The components of diagnosis
Though the availability of many clinical signs for DVT-PE, the expert-based diagnosis of VTE is considered unreliable 3, 4 . Underdiagnosed cases can erroneously attach a DVT-PE label to a patient and be the premise of a low quality prevention and treatment of any future thromboembolic adverse effect. 
PTP tools, laboratory assays

PTP tools
VTE risk is dependent on the duration of inactivity: induced (anesthesia, surgery) or forced (coma, life-support, paresis, life-threatening illnesses and so on). Most risk assessment scores now take this into consideration.
Several scores are available for VTE (Table II) . In order not to ingenerate any confusion, it is worth to describe them shortly.
The most used tools for the assessment of pre-test probability (PTP) in venous thromboembolism (VTE) are:
Wells DVT score 5, 6 (Table III) , Wells PE score 7 (Table   IV) , Revised Geneva score 8 (Table V) and the pulmonary embolism rule-out criteria (PERC rule) 9, 10, 11, 12 (Table VI) .
Other scores are not for diagnosis. The Caprini   13 and Padua 14 (Table VII) scores quantify the risk of thromboembolism and are useful only for VTE prevention among in-patients. The PESI score 15 (Table VIII) and its simplified form sPESI score (Table IX) stratify the risk of outcome and death at 30 days in patients suffering for a PE episode. The HASBLED score 16 (Table X) quantifies instead the risk of bleeding, when the patient undergoes oral anticoagulation.
The idea of risk stratification (or pre-test probability) in Wells DVT score was based solely on the population of symptomatic ambulatory patients. Wells PE Score, Geneva and Revised Geneva scores were designed instead for the emergency room (ER). , attempts to do the same for other populations (pregnant and post-partum, cancer, recent trauma or surgery, obesity etc) either failed or have not been suggested.
PTP Tools Scores
It is worth reminding once and forever that the postoperative period is not the main cause of VTE, which is much more frequent in the medical department than in the surgical one.
Some of the listed tools are generally not well known by physicians and are also used in an inappropriate way. Indeed, scores used alone have generally no diagnostic value. They serve instead to classify the patient into risk classes. Subsequent diagnostic choices depend on the selected class. Wells DVT Score is designed and validated to be used only in ambulatory outpatients. When VTE is suspected at the visit, the score is computed: if low, ask for a D-Dimer assay; if otherwise it is high, prescribe a Duplex UltraSound (DUS). The patient goes home and comes back (if not lost), generally in 7-15 days with the results. The physician waits a so long time for a diagnostic assessment and only the ambulatory environment can justify it, because the patient generally has no urgent symptom. The tree-like hierarchy of the algorithm can be explained only by the ambulatory environment. Wells DVT Score cannot be applied and is not validated in the ER , where a D-Dimer can be obtained in 1-2 hours following traditional laboratory methods, but also in 5'-20' using specialised bedside assays which are not so rare nowadays.
ERs use instead the Geneva 18 or the Wells PE score for people suspected for an important VTE, which can have life-threatening consequences. In addition, the PERC rule (Pulmonary Embolism Rule-out Criteria) is often used, which has the advantage of being simple and quick. If all the listed items in PERC are satisfied, pulmonary embolism is ruled-out. In addition, the efficiency of the PERC rule can be improved introducing also the Gestalt, i.e. the personal intuition of the operator about the presence/absence of PE. 
Laboratory assays
Laboratory assays are useful as the clinical signs and symptoms of VTE are nonspecific, the accuracy of clinical diagnosis being less than 50%. It would be useful to use biomarkers that enable early identification of patients at high or low risk of primary and recurrent VTE. Several established and new biomarkers associated with VTE have been investigated with regard to their potential for predicting primary or recurrent VTE, for facilitating the diagnosis and for optimizing the clinical management of VTE. Clinicians must be aware that D-dimer is increased in many conditions. Physiologic causes of D-dimer elevation include pregnancy and puerperium, increasing age (>65 years), Afro-American heritage, cigarette smoking, recent trauma, and the postoperative period. Pathological causes for elevated D-dimer levels are: VTE, arterial thrombosis, atrial fibrillation, liver disease, renal disease, infections, malignancy and its treatment, chronic inflammatory disease, etc. High-PTP patients should not be tested for D-dimer because the post-test probability for a D-dimer >500 µg FEU/l has a poor positive predictive value for VTE. However, a negative D-dimer is useful in ruling out VTE in low-PTP patients. The cutoff threshold may differ over age groups, for instance in the elderly an increased value of >750 µg FEU/l was proposed. Many factors play a key role in changing the sensitivity and specificity of D-dimer testing, including the extent of thrombosis and fibrinolytic activity, duration of symptoms, anticoagulant therapy, comorbidity due to surgical or medical illnesses, inflammatory diseases, cancer, elderly age, pregnancy and the postpartum period, and previous VTE.
D-Dimer
Many studies have shown that the D-dimer test is highly sensitive (>95%) in acute deep venous thrombosis or pulmonary embolism, usually with a cut-off value of 500 µg FEU/l, which reasonably rules out acute VTE in low-PTP patients. Patients with high D-dimer levels upon presentation may prompt a more intense diagnostic approach, irrespective of pretest probability. Studies performed after a negative D-dimer for 3 months proved the high negative predictive value (NPV) of D-dimer testing in low-PTP patients with suspected VTE. The combination of the D-Dimer and Wells criteria can in significantly reduce the number of patients referred for venous Duplex ultrasound. In unselected inpatients, D-dimer testing has limited clinical utility because of its poor specificity. D-dimers are detected by immunoassays using monoclonal antibodies specific for the crosslinked D-dimer domain in fibrinogen. Commercially available assays include latex agglutination, immunoturbidimetry, and enzyme-linked immunosorbent assay (ELISA). Efforts made to standardize D-dimer results have not been successful thus far, because the D-dimer analyte is not uniform across the different assays 23 .
sP-selectin
Soluble P-selectin 24,25 (sP-selectin) is a member of the selectin family of cell adhesion molecules and is primarily stored in the alpha granules of platelets and the Weibel-Palade bodies of endothelial cells. After activation of platelets and endothelial cells, P-selectin is translocated to the cell surface and in part released into the plasma in soluble form. P-selectin acts through binding to its main counterreceptor, the P-selectin glycoprotein ligand-1 (PSGL-1), located on leukocytes. P-selectin is an important molecule in hemostasis and thrombosis. The P-selectin receptor, PSGL-1, is also expressed on platelets and mediates platelet-endothelium interaction and supports fibrin formation and thrombus growth. The interaction of P-selectin and its receptor leads to several mechanisms that induce a pro-coagulant state. Studies have demonstrated the clinical significance of P-selectin for thrombosis, and elevated sP-selectin has been implicated as a risk factor for venous thromboembolism. sP-selectin levels have been observed to increase during an acute event of VTE. There is growing evidence that platelet activation results in higher levels of sP-selectin, and it can be assumed that sP-selectin is mainly platelet-derived and reflects platelet activation.
Plasma levels of sP-selectin are elevated in acute DVT. Further, high levels of sP-selectin were recently associated with an increased risk for recurrence of DVT and in cancer patients, high plasma levels of sP-selectin were predictive of VTE. In one study soluble sP-selectin in combination with the Wells score, established the diagnosis of DVT in lower limbs with a specificity of 96% and a positive predictive value of 100%. Another recent study showed that when Wells score >2, sPselectin is an excellent biomarker to rule in DVT in lower limbs. Ddimer and a Wells score <2 was most sensitive at excluding a diagnosis of DVT. However the clinical applicability of sP-selectin measurements to assess the risk of VTE needs to be standardized and investigated in greater extent in interventional trials.
Oximetry and Acid Base Balance
Essentially, PE affects the oxygen transport and changes can be detected by means of the following measurements: oximetry, with detection of low peripheral oxygen saturation (SpO 2 ) and Acid Base Balance (ABB). As regards the ABB, there are 3 parameters:
ABB parameters and PE -1. Hypoxia (low arterial pO 2 ) and hypocapnia (low arterial CO 2 ); -
The first two ABB parameters can be measured with in an arterial/ capillary sample, whilst the third one requires an arterial and a central venous sample [26] [27] [28] . Though very informative of the severity of pulmonary embolism, AAB parameters are not included in any officially recognized diagnostic algorithm for PE. Apart of measurement errors, a general relationship should generally hold:
S a O 2 >= S p O 2 >= S v O 2
where SO 2 is the oxygen % hemoglobin saturation and the subscripts a, p and v mean arterial, peripheral and venous respectively.
The revised Geneva score 
of a D-dimer test is 25$ in Brasil and it takes 3 days for the result while a DUS costs 45$ and is quickly available. After the DUS we probably don't need D-dimer but after D-dimer we probably will ask for DUS. In private practice usually the doctor doesn't have time to wait, he argues, thus the question arises why not asking directly for DUS.
In conclusion almost all discussants agreed with the utility of biomarkers, especially of D-dimer in the diagnostic algorithm of VTE in combination with a clinical probability score and an imaging method (ultrasound and/or CTPA).
Available imaging methods
Ultrasound TTE
Trans-Thoracic Echocardiography (TTE) can add useful information. Right heart chambers dimensions can increase considerably their diameters in acute PE. The pulmonary artery tension can be non-invasively estimated from right chambers velocimetry and inferior vena cava caliber and pulsatility. In addition, the Tricuspid Annular Plane Systolic Excursion (TAPSE) can evaluate the diastolic function of right heart chambers. These observation can help in assessing patients with PE or chronic thromboembolic pulmonary hypertension (CTEPH) and can match the corresponding changes in the electrocardiogram, which however are more reliable in chronic pulmonary hypertension (CPH).
DUS
Duplex ultrasonography (DUS) is a recognized ultrasound diagnostic tool in vascular diseases and of course in venous pathology. A training period (at least 2 years) is required to prepare a skilled ultrasonographer. Owing to its complexity DUS cannot be described here, thus we refer to any available educational text.
The pulmonary embolism rule-out criteria (PERC rule) 
CUS
Compression ultrasonography (CUS) may be proficiently learned in <2 hours. It was developed as a quick and simple emergency tool, in order to give reliable results in cases of suspected DVT [29] [30] [31] [32] [33] . It requires only a simple BMode scan of groin and popliteal region (2-points ultrasonography), where observation can be extended to the 3rd order confluence of anterior and posterior tibia and peroneal veins. This extension however is debated, because it is a more difficult manoeuvre which requires a longer training period.
Simple BMode scanning is used to look at the saphenousfemoral junction (SFJ) and saphenous-popliteal junction (SPJ), which can just visualize the thrombus inside the lumen, so providing the diagnosis.
A soft compression of the cited veins with the echo probe can show the flexible state of their wall. When the vein is compressible, CUS is negative, when the vein is rigid CUS is positive. In almost all cases compressibility implies patency, while rigidity implies occlusion. Other difficult cases are the absence of the greater saphenous vein or of the shorter saphenous vein, as normal anatomy is changed.
CUS is a valid tool in proximal lower limb symptomatic DVT, with a sensitivity of 97% and specificity of 98%. In lower limb distal DVT results are conflicting.
When the pre-test probability is high or the clinical suspicion is important and CUS is negative, it is possible to use a second CUS at 1 week. This second look or serial CUS can be used also to monitor the patient (when symptoms persist or increase) or in the post-operative period in patient at high risk.
CUS is a separate exam, not a DUS, though this latter includes compression on veins. In addition, DUS can visualize the echogenicity of the venous thrombus, its adherence to the venous wall and its mobility inside the lumen (floating thrombus). DUS looks also at flow (absent / present) and at its changes during breathing and functional manoeuvres.
Figure 2 -The VLab CUS form for the Emergency Room
Patients with suspected DVT of the lower limbs are usually investigated with CUS or DUS. The latter approach has a much greater diagnostic capability, as for instance its ability to detect isolated calf vein thrombosis. However, it requires skilled operators and depends on the availability of an experienced ultra-sonographer mainly during the ordinary working hours. A prospective, randomized, multicenter study of consecutive symptomatic outpatients (n=2465) with a first episode of suspected DVT of the lower extremities shows that 2 diagnostic strategies (1. CUS+D-dimer when CUS is normal, 2. whole length DUS) are equivalent when used for the management of symptomatic Journal of Theoretical and Applied Vascular Research (page 88) -JTAVR 2016;1(2):81-94 outpatients with suspected DVT of the lower extremities. Relevant features of this strategy are simplicity, reproducibility, and broad availability. There is the need to repeat the test within 1 week (serial CUS) in patients with normal findings at presentation and positivity of D-dimer. With DUS strategy color flow is exploited to enhance small vessel visualization, although vein compressibility still constitutes the main diagnostic criterion. The advantage of the DUS approach is the ability to exclude isolated calf DVT, allowing for 1-day low molecular weight heparin (LMWH) treatment of all patients, eventually stopping the therapy in case of negative DUS without any additional testing. Conversely, it needs top-quality ultrasound equipment and experienced operators; therefore, it is often unavailable after hours and during the weekends.
Other imaging techniques
The diagnosis of pulmonary embolism (PE) remains a common challenge confronting physicians in daily clinical practice. PE is considered in the differential diagnosis of many clinical presentations and in a wide variety of clinical settings. Ventilation-perfusion lung scanning (V/Q) has been the non-invasive imaging procedure of choice in patients with suspected PE for many years. However, a majority of patients with suspected PE undergoing a ventilation-perfusion scan have a non-diagnostic examination (low or intermediate probability of PE). The prospective investigation of the pulmonary embolism diagnosis 34, 35 (PIOPED) study shows that clinical assessment combined with the ventilation/perfusion scan established the diagnosis or exclusion of pulmonary embolism only for a minority of patientsthose with clear and concordant clinical and ventilation/perfusion scan findings. In PIOPED era the gold standard was pulmonary angiography.
More recently, the computed tomographic pulmonary angiography (CTPA) has been introduced as an alternative non-invasive test. A CTPA provides a clear result (either positive or negative for PE) and possibly an alternative diagnosis to explain the patient's symptoms. Multiple-detectors CTPA have a higher sensitivity for PE as compared with single-detector CTPA. In particular, multiple-detectors CTPA allows better visualization of segmental and subsegmental pulmonary arteries. However, V/Q scintigraphy could have a similar or even higher sensitivity than CTPA in detecting CTEPH as a potential curable cause of pulmonary hypertension 36 . CTPA is now preferred as the first-choice test for PE by both scientific societies and practicing physicians. The increased sensitivity of CTPA may have a downside: the detection of emboli that are so small as to be clinically insignificant.
This phenomenon has been called "overdiagnosis", defined as the detection of an abnormality that will never cause symptoms or death 37, 38 . Overdiagnosis matters because it can lead to iatrogenic harm. While a clinically non-significant PE is by definition not harmful, treating such an embolism can cause harm (e.g., bleeding from anticoagulation, which can in the worst case be fatal). On the other site of the coin is CTEPH as a consequence of repetitive emboli even if they are small. The judicious balance between these two ends of the spectrum of the disease needs further investigations. For certain patient groups, such as patients with contraindications to iodinated contrast media and young women (possibility of pregnancy) with a low PE-PTP, magnetic resonance (MRI) can be considered as a first-choice imaging tool for PE assessment. Recent technical developments have substantially improved the potential of MRI for PE diagnosis 39, 40 , as the development of short magnets and dedicated whole-body MRI systems together with the dynamic gadolinium enhancement, which allow a comprehensive evaluation of pulmonary embolism and deep venous thrombosis in a single exam. The introduction of parallel imaging has substantially improved the spatial and temporal resolution of pulmonary MR angiography. By combining timeresolved pulmonary perfusion MRI with high-resolution pulmonary MRA a sensitivity and specificity of over 90% is achievable, which is comparable to the accuracy of CTPA 41 .
The PESI score 
There are two weak points in this argumentation, replies F Passariello. First of all what D Casian says can be true for lower limbs DVT, but is undoubtedly false for DVT-PE, as thrombosis can be everywhere and often the source of PE cannot be found, he argues. A consultation for a suspected DVT often is not a very urgent examination. People can wait one day or more for the exam, according to the availability of the specialist (for instance not at work now or in holidays). Try to apply this unavailability to a suspected PE, which can be a very critical disease (must enter or not ICU or coronary unit? must start a systemic thrombolysis ?). Time is a very high cost. F Passariello thinks that an always-available simple CUS can give a much better service than an inconstant DUS service on demand. Finally, he suspects also that D Casian's false negative rate is much greater for DVT-PE than for DVT only. Secondly though he is a Vascular Surgeon, he doesn't think that Vascular Surgeons are the best professional profile to put an indication to DUS for VTE (DVT-PE) patients. Generally Vascular Surgeons are not involved in the use of scores, CUS, DUS, D-Dimer, sP-selectin and so on. The danger is that the indication could be given following common opinions and not what is reported in the literature and the guidelines. VTE patients show a clinical presentation in a range from life-threatening cases (cardiac arrest, acute respiratory failure, hemopthysis) to no relevance ones, with only a few not important symptoms or no one at all.
A Pieri comes into the discussion arguing with the followings: PE is normally present (always) when one sees a DVT at any location (Angio CT scan always reveals small PE). Only clinically relevant PE needs hospitalization and rarely fibrinolysys. Fatal PE is fatal! Otherwise full dose subcutaneous Heparin treatment is enough, waiting for a "second degree" diagnosis. We only need to make a "correct" Color Duplex diagnosis. CUS is not a good diagnosis because Doppler investigation is not included and because upper limbs (subclavian DVTs) and distal DVTs are not considered. Distal DVT are often the marker of PE (residual DVT after embolisation). DUS investigation of abdomen can reveal iliac, renal, ovarian, etc. locations of DVT, CUS and probability scores would not be allowed, in his mind, in a great Hospital. CUS could even be DANGEROUS in cases of proximal floating DVT (femoral-iliac)! We have only to decide when a CT scan is needed and when to investigate patients for cancer !! DDimer false positive (trauma or surgical patients) give no value to this kind of investigation that must be avoided (obviously in his mind
A Pieri says that indication of Cava filter is extremely rare nowadays. He states also that CUS is obviously included in DUS and that the first approach to DVT is heparin, then one can investigate for PE. F Passariello reminds the details of CUS and DUS (already outlined above in the text) and states that CUS is a separate exam and not a DUS. The latter of course includes compression of veins (everywhere and not only 2 points), but DUS does not consider venous compression as a step of a clinical algorithm. Thus though it uses compressions DUS does not include CUS. M Schul says that overutilization of CUS/DUS
Algorithms
The British National Institute for Health and Care Excellence 44 (NICE) developed two important algorithms, the first for DVT, the latter for PE. Here we will take them just as an example of all the other existing algorhitms. Both are drawn for the ER or for a structure able to insure very quick evaluations. This is an important point, because the Wells DVT score is used in an ER environment, other than ambulatorial.
Both algorithms consider a short term(4h) ultrasound availability. DUS is not cited at all, while the term proximal ultrasound appears as a substitute for CUS.
In this regard several legitimate questions arise:
-is the proximal ultrasound term an analogous for a proximal CUS, i.e. performed only at the SFJ ?
-Is there an evidence-based medicine (EBM) available reference for the proximal CUS ? -Is the proximal CUS documented to have the same sensitivity of a complete CUS.
-In addition, when time needed to get an ultrasound investigation is >4h and reaches 1 day or more, why not having a complete DUS instead of a CUS ? The same question holds if a repeated examination is needed one week later.
The reported flow charts are clear: always perform a score, there is no doubt about. However, scores are different for DVT and PE, though they are both Wells score. Why Wells PE and not Geneva for PE ? Wells PE is more operator dependent, because one of the items is subjective, exactly where the score asks if there is an alternative diagnosis. Geneva instead is operator independent and more repeatable. Interestingly, an interim treatment with heparin is always planned when investigations are not soon available. This feature means that NICE algorithms can be regarded as mixed ones, i.e. diagnostic + therapeutic. It seems that for the more urgent and life-threatening cases the diagnosis must be mixed with the therapy.
The PE NICE algorithm plans a reduced time threshold of 1h instead of 4h in order to choose between ultrasound and D-Dimer and introduces also CTA between diagnostic tools. In addition, the PE flow chart is graphically redundant, thus it could be simplified becoming more readable, but leaving the content unchanged.
Another last observation deals with the choice between these algorithms and the other ones we saw for the outpatients. In simple words, outpatients flow-charts should be modified to allow exiting with the urgent need of shortening the procedures, i.e. sending the patient from the ambulatory to the hospital or to the ER.
Conclusions
At the end of the discussion, the Moderator F Passariello tries to resume the still unclear and open points.
There are two great approaches in VTE diagnosis:
A. The imaging techniques are constituted in general by an anatomic and hemodynamic point of view, the detection of thrombosis being based definitely on its visibility In this group also the pressure evaluation is included (an endo-venous invasive measurement as well as a non-invasive one), as it deals with a mixed anatomical/ hemodynamic context. Examples in this group are: CUS, Duplex, phlebography, pulmonary angiography, CTA, MRA, V/Q scintigraphy, endo-venous catheter pressure measurement, non-invasive pressure measurements, etc.
B. The statistical tools include the scores and the biomarkers assays and clarify if thrombosis exists or not, but do not say nothing about its anatomical localization Examples are Wells (DVT and PE) scores, revised Geneva, PERC rule, D-Dimer, sP-selectin.
The contra-opposition is evident. The fans of the imaging methods will look with suspect at scores and biomarkers, asking instead "where" thrombosis is located and which are its features. On the other side, the fans of the statistical tools will criticise the negative findings of the imaging techniques, because very often thrombosis hides itself and it is very difficult to find it: if you are not able to see thrombosis, it doesn't mean that it is not there.
In addition, there are two great styles in VTE diagnosis: a. the expert opinion which is more near to the clinicians' mind, with all the criticism which can be moved to it. Clinical judgements like the "Gestalt" associated to the PERC rule are included in this group. Also DUS (with the clinical and instrumental intuition associated to the use of the "III Chakra Eye" constituted by the ultrasound probe) gives the opportunity of expressing an expert opinion.
b. The standard forms and procedures of the algorithms pertain instead to another style, very near to EBM Medicine, which tries to limit as much as possible the role of the expert opinion in medical procedures.
